Resumen de acción 6855 Ascentage Pharma Group International, empresa biotecnológica en fase clínica, desarrolla terapias contra el cáncer, el virus de la hepatitis B crónica (VHB) y enfermedades relacionadas con la edad en China continental. Saber más
Recompensas Análisis de riesgos Ver todos los controles de riesgos Captura tus ideas, enlaces y narrativas de la empresa
Competidores de Ascentage Pharma Group International Historial de precios y rendimiento
Resumen de las cotizaciones máximas, mínimas y variaciones del Ascentage Pharma Group International Precios históricos de las acciones Precio actual de la acción HK$42.95 Máximo en las últimas 52 semanas HK$48.85 Mínimo de 52 semanas HK$15.42 Beta 1.13 Cambio en 1 mes 1.30% Variación en 3 meses 10.70% Cambio de 1 año 69.09% Variación en 3 años 62.69% Variación en 5 años 41.52% Variación desde la OPV 14.23%
Noticias y actualizaciones recientes
Ascentage Pharma Releases the Safety and Efficacy Data of the Novel Drug Candidate, Olverembatinib (HQP1351) in Combination the Company's Investigational Novel Bcl-2 Inhibitor, Lisaftoclax Dec 10
Ascentage Pharma Announces New Indication of Olverembatinib Included into China 2024 National Reimbursement Drug List Nov 28
Ascentage Pharma Appoints Marina S. Bozilenko and Debra Yu as Independent Non-Executive Directors Nov 27
Ascentage Pharma Received CDE Clearance for Registrational Phase III Studies of APG-2449 for Treatment of Patients with NSCLC Oct 08
First half 2024 earnings released: EPS: CN¥0.56 (vs CN¥1.47 loss in 1H 2023) Oct 03
Ascentage Pharma Group International's (HKG:6855) Shares Climb 26% But Its Business Is Yet to Catch Up Sep 04 Ver más actualizaciones
Ascentage Pharma Releases the Safety and Efficacy Data of the Novel Drug Candidate, Olverembatinib (HQP1351) in Combination the Company's Investigational Novel Bcl-2 Inhibitor, Lisaftoclax Dec 10
Ascentage Pharma Announces New Indication of Olverembatinib Included into China 2024 National Reimbursement Drug List Nov 28
Ascentage Pharma Appoints Marina S. Bozilenko and Debra Yu as Independent Non-Executive Directors Nov 27
Ascentage Pharma Received CDE Clearance for Registrational Phase III Studies of APG-2449 for Treatment of Patients with NSCLC Oct 08
First half 2024 earnings released: EPS: CN¥0.56 (vs CN¥1.47 loss in 1H 2023) Oct 03
Ascentage Pharma Group International's (HKG:6855) Shares Climb 26% But Its Business Is Yet to Catch Up Sep 04
Consensus revenue estimates increase by 40% Aug 29
Forecast to breakeven in 2026 Aug 28
Here's Why Ascentage Pharma Group International (HKG:6855) Can Afford Some Debt Aug 26
First half 2024 earnings released: EPS: CN¥0.56 (vs CN¥1.47 loss in 1H 2023) Aug 26
New major risk - Revenue and earnings growth Aug 23
Ascentage Pharma Clears to Initiate A Registrational Phase III Study of Lisaftoclax, by the Center for Drug Evaluation of China National Medical Products Administration Aug 13
Ascentage Pharma Group International to Report First Half, 2024 Results on Aug 22, 2024 Aug 09
New minor risk - Shareholder dilution Jun 24
Ascentage Pharma Group International's (HKG:6855) Shares Climb 29% But Its Business Is Yet to Catch Up Jun 18
Ascentage Pharma Announces Updated Results from Three Studies of Olverembatinib (HQP1351) Jun 18
New minor risk - Share price stability Jun 17
Ascentage Pharma Group International Announces Board and Committee Changes Jun 13 Ascentage Pharma Releases Updated Clinical Data of olverembatinib in SDH-Deficient GIST, Including a CBR of 92.3%
Ascentage Pharma Releases Latest Results from Multiple Clinical Studies of Its Lead Drug Candidates in 2024 American Society of Clinical Oncology Annual Meeting May 25
Here's Why Ascentage Pharma Group International's (HKG:6855) CEO May Not Expect A Pay Rise This Year May 03
Consensus EPS estimates fall by 15% Apr 03
Why We're Not Concerned Yet About Ascentage Pharma Group International's (HKG:6855) 30% Share Price Plunge Mar 30
Ascentage Pharma Group International, Annual General Meeting, May 10, 2024 Mar 28
Full year 2023 earnings released: CN¥3.28 loss per share (vs CN¥3.35 loss in FY 2022) Mar 28
Ascentage Pharma Group International to Report Fiscal Year 2023 Results on Mar 27, 2024 Mar 16
Ascentage Pharma to Present Three Preclinical Studies at 2024 American Association of Cancer Research Annual Meeting Mar 06
Are Investors Undervaluing Ascentage Pharma Group International (HKG:6855) By 40%? Feb 17
Ascentage Pharma Receives Clearance from the US Food and Drug Administration to Initiate Global Registrational Phase III Trial of Olverembatinib (HQP1351) in Patients with Chronic-Phase Chronic Myeloid Leukemia Feb 14
Ascentage Pharma Announces Olverembatinib Included in Newest Guidelines on Chronic Myeloid Leukemia (CML) Management from the National Comprehensive Cancer Network (NCCN) Jan 17
There's Reason For Concern Over Ascentage Pharma Group International's (HKG:6855) Price Dec 20
Ascentage Pharma Group International Presents Preliminary Results from A Phase II Study of Novel Drug Candidate, Olverembatinib Dec 15
Ascentage Pharma Group International Releases the First Dataset of BCL-2 Inhibitor Lisaftoclax in Patients with R/R Mm, Demonstrating Encouraging ORR and VGPR Dec 11
Ascentage Pharma Announces the Launch of Olverembatinib in Newly Approved Indication and the Dispatch of First Batch for the New Indication Nov 25
China National Medical Products Administration Approves Olverembatinib for Treatment of Cml-Cp Patients Nov 18 Ascentage Pharma Group International to Present Results from Multiple Clinical Studies of olverembatinib and APG-2575 at the 2023 American Society of Hematology(ASH) Annual Meeting, two of which have been Selected for Oral Reports
Ascentage Pharma Group International (HKG:6855) Is Making Moderate Use Of Debt Oct 28
Ascentage Pharma Releases Latest Data of Pelcitoclax (Apg-1252) Combined with Osimertinib Demonstrates Potential as A New Treatment Option for Tp53-And Egfr-Mutant Nsclc Oct 24
Ascentage Pharma Announces First Patient Dosed in the Registrational Phase III Study of Olverembatinib in Treatment-Naïve Patients with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia Oct 18
Ascentage Pharma Announces Global Registrational Phase III Study of Bcl-2 Inhibitor Lisaftoclax in Treatment Naïve Patients with CLL/SLL Approved by the China CDE Oct 13
Consensus revenue estimates fall by 12% Aug 28
Some Analysts Just Cut Their Ascentage Pharma Group International (HKG:6855) Estimates Aug 27
First half 2023 earnings released: CN¥1.47 loss per share (vs CN¥1.54 loss in 1H 2022) Aug 23
There's Reason For Concern Over Ascentage Pharma Group International's (HKG:6855) Price Aug 23
Ascentage Pharma Announces Clearance for Global Registrational Phase III Trial Aug 22
Ascentage Pharma Group International to Report First Half, 2023 Results on Aug 21, 2023 Aug 10
Ascentage Pharma Group International Receives Clearance from the U.S. Food and Drug Administration to Initiate A Phase 3 Registrational Trial of Lisaftoclax Aug 08
Ascentage Pharma Group International Announces CDE's Approval for the Phase III Pivotal Study in China of Olverembatinib for the Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ All) Jul 06
Ascentage Pharma Group International (HKG:6855) Is Carrying A Fair Bit Of Debt Jun 19
Ascentage Pharma Group International Releases Updated Data Showing APG-2449's Potential as a New Treatment for Drug-Resistant NSCLC Jun 06
Ascentage Pharma Group International Recommends Breakthrough Therapy Designation in China for the Treatment of Sdh-Deficient GIST Jun 01
Ascentage Pharma Group International Presents Results from Four Studies at 2023 American Society of Clinical Oncology Annual Meeting May 29
Consensus revenue estimates decrease by 22%, EPS upgraded Mar 29
Full year 2022 earnings: EPS and revenues miss analyst expectations Mar 23 Ascentage Pharma Group International has completed a Follow-on Equity Offering in the amount of HKD 550.125 million. Feb 02
Ascentage Pharma Group International's Third-Generation BCR-ABL Inhibitor Olverembatinib Included into the 2022 National Reimbursement Drug List Jan 19
Ascentage Pharma Group International Releases Preliminary Results from a Global Phase II Study of Lisaftoclax Dec 14 Ascentage Pharma Delivers Oral Report on the First Dataset from the US Study of Olverembatinib (HQP1351) with Promising Efficacy Observed in Patients Who Failed Prior Treatment with Ponatinib
Ascentage Pharma Group International (HKG:6855) Has Debt But No Earnings; Should You Worry? Dec 04
Ascentage Pharma's Global Industrial Base Obtains Drug Production Enterprise License Nov 28
Ascentage Pharma Group International Announces IND Approval in China for Phase I Study of APG-5918 in Patients with Advanced Solid Tumors or Hematologic Malignancies Nov 10
Ascentage Pharma Group International Announces Released Results from A Phase I Study of the Investigational Inhibitor of Apoptosis Protein (Iap) Antagonist Apg-1387 in Chinese Patients with Chronic Hepatitis B Nov 08
Ascentage Pharma Releases Phase I Results of Iap Antagonist Apg-1387 in an Oral Report Showing Potential for Functionally Curing Chb Nov 07
Co-Founder recently bought HK$159k worth of stock Nov 06 Ascentage Pharma to Present Data of Olverembatinib (HQP1351) in Three Oral Reports, Including the First Dataset from the First US Study, At the ASH Annual Meeting Nov 04
Ascentage Pharma to Announce Results from First-in-Human Study of IAP Antagonist APG-1387 in an Oral Report at the AASLD Annual Meeting Oct 20 Ascentage Pharma Announces Phase I/Ii Data of Olverembatinib (Hqp1351) Published in the Journal of Hematology & Oncology, Further Validating the Drug's Best-In-Class Potential
Is Ascentage Pharma Group International (HKG:6855) A Risky Investment? Aug 30
First half 2022 earnings released: CN¥1.54 loss per share (vs CN¥1.53 loss in 1H 2021) Aug 29
Ascentage Pharma Group International to Report Q2, 2022 Results on Aug 26, 2022 Aug 17
High number of new directors Jul 31
Ascentage Pharma Announces Clinical Trial Application for Olverembatinib (HQP1351) Approved in Canada Jul 22
Ascentage Pharma Announces China National Medical Products Administration Accepts and Grants Priority Review Designation to Drug Application for Olverembatinib for the Treatment of Drug-Resistant CML Jul 20 Ascentage Pharma Group International Announces Ind Clearance by the Us Fda for First-In-Human Study of Novel Eed Inhibitor Apg-5918
Ascentage Pharma Group International Releases Results from A Phase I Study of the Company's Novel Bcl-2-Selective Inhibitor Lisaftoclax (APG-2575) in Chinese Patients with Relapsed/Refractory Non-Hodgkin Lymphoma (R/R Nhl) at the 2022 European Hematology Association Hybrid Congress Jun 13
Ascentage Pharma Releases Updated Data Demonstrating Lisaftoclax's (APG-2575) Therapeutic Potential in Patients with R/R CLL/SLL Jun 09
Ascentage Pharma Releases for the First Time Results of its FAK/ALK/ROS1 inhibitor APG-2449 Demonstrating Safety and Efficacy in Patients with Advanced NSCLC Jun 08 Ascentage Pharma Group International Releases the Updated Results from A Phase II Study of the Mdm2-P53 Inhibitor Alrizomadlin (APG-115) Plus Pembrolizumab in Adults and Children with Various Solid Tumors in A Poster Discussion Session At the ASCO Annual Meeting
Ascentage Pharma Presents Updated Results from Multiple Clinical Studies Demonstrating Rapid Progress in Global Clinical Development May 27
High number of new directors May 26
Ascentage Pharma Group to Present Latest Clinical Data of Bcl-2 Inhibitorlisaftoclax (Apg-2575) in Patients with Relapsed/Refractory Non-Hodgkinlymphomas At 2022 European Hematology Association Hybrid Congress May 24
Ascentage Pharma Group International Announces Management Changes, Effective May 20, 2022 May 20
Ascentage Pharma Group International Announces Preclinical Data Demonstrating Olverembatinib's Therapeutic Potential in Treating COVID-19 Published in Embo Molecular Medicine May 19
Less than half of directors are independent Apr 27
Ascentage Pharma Presents Latest Results from Six Preclinical Studies at AACR Annual Meeting 2022 Apr 14
Ascentage Pharma Group International, Annual General Meeting, May 19, 2022 Mar 23
Ascentage Pharma Presents Latest Data from Two Studies of Bcl-2-Selective Inhibitor Lisaftoclax (APG-2575), Including A China Study Demonstrating Complete Responses Dec 15
Ascentage Pharma Announces CDE's Approval for the Phase II Pivotal Study in China of the Bcl-2 Inhibitor Lisaftoclax (APG-2575) for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Dec 13
Clover Biopharmaceuticals, Ltd. and Ascentage Pharma Announce Clinical Collaboration to Evaluate Recombinant Human Trail-Trimer Fusion Protein, SCB-313, in Combination with IAP Antagonist, APG-1387 for the Treatment of Peritoneal Carcinomatosis Dec 10
Ascentage Pharma and Innovent Biologics Announce Approval for China's First Third-Generation BCR-ABL TKI Olverembatinib Dec 01
Does Ascentage Pharma Group International (HKG:6855) Have A Healthy Balance Sheet? Oct 04
Ascentage Pharma's MDM2-p53 Inhibitor Alrizomadlin (APG-115) Grants Fast Track Designation by the US FDA for the Treatment of Relapsed/Refractory Unresectable or Metastatic Melanoma Sep 24 Rentabilidad de los accionistas 6855 HK Biotechs Mercado HK 7D 11.0% -3.9% -0.5% 1Y 69.1% -5.7% 19.9%
Ver rendimientos de los accionistas
Rentabilidad vs. Industria: 6855 superó a la industria Hong Kong Biotechs, que obtuvo un rendimiento del -5.7% el año pasado.
Rentabilidad vs. Mercado: 6855 superó al mercado Hong Kong, que obtuvo un rendimiento del 19.9% el año pasado.
Volatilidad de los precios Is 6855's price volatile compared to industry and market? 6855 volatility 6855 Average Weekly Movement 6.3% Biotechs Industry Average Movement 11.1% Market Average Movement 8.8% 10% most volatile stocks in HK Market 18.6% 10% least volatile stocks in HK Market 4.1%
Precio estable de las acciones: 6855 no ha tenido una volatilidad de precios significativa en los últimos 3 meses.
Volatilidad a lo largo del tiempo: La volatilidad semanal de 6855 (6%) se ha mantenido estable durante el año pasado.
Acerca de la empresa Ascentage Pharma Group International, empresa biotecnológica en fase clínica, desarrolla terapias contra el cáncer, el virus de la hepatitis B crónica (VHB) y enfermedades relacionadas con la edad en China continental. El principal producto candidato de la empresa es HQP1351, un inhibidor de BCR-ABL dirigido a mutantes de BCR-ABL1, incluidos los que presentan la mutación T315I. También desarrolla APG-2575, un inhibidor selectivo de Bcl-2 administrado por vía oral para neoplasias hematológicas y tumores sólidos; APG-115, un inhibidor oral de molécula pequeña de las interacciones proteína-proteína MDM2-p53 para tratar tumores sólidos y neoplasias hematológicas; y APG-1252, un fármaco de molécula pequeña para restaurar la apoptosis mediante la inhibición dual de las proteínas Bcl-2 y Bcl-xL para el tratamiento del cáncer de pulmón microcítico, el cáncer de pulmón no microcítico, el tumor neuroendocrino y el linfoma no hodgkiniano.
Mostrar más Resumen de fundamentos de Ascentage Pharma Group International ¿Cómo se comparan los beneficios e ingresos de Ascentage Pharma Group International con su capitalización de mercado? Estadísticas fundamentales de 6855 Capitalización bursátil HK$13.31b Beneficios(TTM ) -HK$383.96m Ingresos (TTM ) HK$962.38m
13.8x Ratio precio-ventas (PS)
-34.7x Ratio precio-beneficio (PE) Beneficios e Ingresos Estadísticas clave de rentabilidad del último informe de resultados (TTM) Cuenta de resultados (TTM ) de 6855 Ingresos CN¥903.03m Coste de los ingresos CN¥27.45m Beneficio bruto CN¥875.58m Otros gastos CN¥1.24b Beneficios -CN¥360.28m
Últimos beneficios comunicados
Jun 30, 2024
Próxima fecha de beneficios
n/a
Beneficios por acción (BPA) -1.16 Margen bruto 96.96% Margen de beneficio neto -39.90% Ratio deuda/patrimonio 216.3%
¿Cómo se ha desempeñado 6855 a largo plazo?
Ver rendimiento histórico y comparativa
Análisis de la empresa y estado de los datos financieros Datos Última actualización (huso horario UTC) Análisis de la empresa 2024/12/21 08:19 Precio de las acciones al final del día 2024/12/20 00:00 Beneficios 2024/06/30 Ingresos anuales 2023/12/31
Fuentes de datos Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC . Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
Paquete Datos Marco temporal Ejemplo Fuente EE.UU. * Finanzas de la empresa 10 años Cuenta de resultados Estado de tesorería Balance Estimaciones del consenso de analistas +3 años Previsiones financieras Objetivos de precios de los analistas Precios de mercado 30 años Precios de las acciones Dividendos, escisiones y acciones Propiedad 10 años Accionistas principales Información privilegiada Gestión 10 años Equipo directivo Consejo de Administración Principales avances 10 años
* ejemplo para los valores estadounidenses, para los no estadounidenses se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Obtenga más información aquí .
Modelo de análisis y copo de nieve Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github , también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube .
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en .
Fuentes analistas Ascentage Pharma Group International está cubierta por 14 analistas. 6 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
Analista Institución Yang Huang BofA Global Research Jin Zhang China International Capital Corporation Limited Wangbin Zhou China International Capital Corporation Limited
Mostrar 11 más analistas 
